INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.400
-0.070 (-4.76%)
At close: Apr 28, 2026, 4:00 PM EDT
1.426
+0.026 (1.86%)
After-hours: Apr 28, 2026, 6:49 PM EDT
INmune Bio Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 0.05 | 0.01 | 0.16 | 0.37 | 0.18 | |
| Revenue Growth (YoY) | 257.14% | -90.97% | -58.56% | 106.63% | 1545.45% | |
| Gross Profit | 0.05 | 0.01 | 0.16 | 0.37 | 0.18 | |
| Selling, General & Admin | 10.26 | 9.48 | 9.62 | 9.26 | 8.79 | |
| Research & Development | 20.66 | 33.17 | 20.27 | 17.07 | 20.54 | |
| Operating Expenses | 30.92 | 42.65 | 29.9 | 26.33 | 29.33 | |
| Operating Income | -30.87 | -42.64 | -29.74 | -25.95 | -29.15 | |
| Interest Expense | - | -0.79 | -2.28 | -2.01 | - | |
| Interest & Investment Income | 0.9 | 1.3 | - | - | - | |
| Other Non Operating Income (Expenses) | -0.05 | 0.04 | 2.01 | 0.67 | -1.19 | |
| EBT Excluding Unusual Items | -30.02 | -42.08 | -30.01 | -27.3 | -30.34 | |
| Other Unusual Items | 0.6 | - | - | - | - | |
| Pretax Income | -45.93 | -42.08 | -30.01 | -27.3 | -30.34 | |
| Net Income | -45.93 | -42.08 | -30.01 | -27.3 | -30.34 | |
| Net Income to Common | -45.93 | -42.08 | -30.01 | -27.3 | -30.34 | |
| Shares Outstanding (Basic) | 25 | 20 | 18 | 18 | 16 | |
| Shares Outstanding (Diluted) | 25 | 20 | 18 | 18 | 16 | |
| Shares Change (YoY) | 24.13% | 10.92% | 0.30% | 11.14% | 34.55% | |
| EPS (Basic) | -1.86 | -2.11 | -1.67 | -1.52 | -1.88 | |
| EPS (Diluted) | -1.86 | -2.11 | -1.67 | -1.52 | -1.88 | |
| Free Cash Flow | -23.62 | -33.36 | -11.98 | -22.69 | -28.5 | |
| Free Cash Flow Per Share | -0.95 | -1.67 | -0.67 | -1.26 | -1.77 | |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | |
| Operating Margin | -61738.00% | -304535.71% | -19187.74% | -6938.77% | -16106.63% | |
| Profit Margin | -91866.00% | -300585.71% | -19360.00% | -7299.20% | -16762.43% | |
| Free Cash Flow Margin | -47248.00% | -238292.86% | -7729.03% | -6065.77% | -15748.07% | |
| EBITDA | -30.79 | - | - | - | - | |
| D&A For EBITDA | 0.08 | - | - | - | - | |
| EBIT | -30.87 | -42.64 | -29.74 | -25.95 | -29.15 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.